Compare Deere & Company (DE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Neurocrine Biosciences Inc — how do they compare? Deere & Company trades at $656.52 (market cap $175.95B), while Neurocrine Biosciences Inc trades at $141.66 (market cap $14.36B). The key difference: Deere & Company is far larger — about 12.3× Neurocrine Biosciences Inc's market cap, and Deere & Company pays a 0.99% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DE | NBIX | |
|---|---|---|
Market Cap | $175.95B | $14.36B |
Volume | 1,387,231 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $709.48 | $185.50 |
52-Week Low | $439.11 | $123.10 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $229.85B | $14.37B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $656.87, down 3.8% on the day, showing near-term weakness despite strong earnings beats in recent quarters. The stock maintains a bullish analyst consensus with a $731.20 price target, representing 11% upside potential. Recent financial performance shows declining revenue from $60.2B in 2023 to $44.7B in 2025, though the company continues generating robust operating cash flow exceeding $7B annually. Technical indicators suggest bearish momentum with the stock trading below key resistance levels.
Deere presents a mixed investment case with attractive valuation upside but faces cyclical headwinds in agricultural equipment demand. The company's AI initiatives and dividend payments provide stability, while declining profit margins and elevated debt levels warrant caution. Wall Street remains optimistic with 43% buy ratings, though technical weakness suggests potential near-term pressure before fundamental strength prevails.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
